

WHAT IS CLAIMED IS:

1. A composition for treating a condition in a mammal, comprising:
a non-steroidal anti-inflammatory drug (NSAID); and
a HER-kinase axis inhibitor.
2. The composition of claim 1, wherein the NSAID is selected from the group consisting of aspirin, diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sunlindac, tenoxicam, tiaprofenic acid, tolmetin, derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.
3. The composition of claim 1, wherein the HER-kinase axis inhibitor is selected from the group consisting of recombinant humanized monoclonal antibody 2C4, ansamycins, gefitinib, erlotinib, monoclonal antibodies, rapamycin, src inhibitors, tyrosine kinase inhibitors, compound LY294002, imatinib mesylate, trastuzumab, compound CI1033, compound PKI166, compound GW2016, compound EKB569, compound IMC-C225, and derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.
4. The composition of claim 1, wherein said NSAID is R-etodolac.
5. The composition of claim 1, wherein said HER-kinase axis inhibitor is recombinant humanized monoclonal antibody 2C4.
6. The composition of claim 1, comprising a quantity of said NSAID of from about 100 to about 500 mg/kg of said mammal.
7. The composition of claim 1, comprising a quantity of said HER-kinase axis inhibitor of from about 5 to about 40 mg/kg of said mammal.
8. The composition of claim 1, wherein the composition is formulated for administration by a technique selected from the group consisting of

intraperitoneal, oral gavage, intravenous, sublingual, topical, intramuscular, intra-arterial, intramedullar, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, parenteral, and rectal.

9. The composition of claim 1, further comprising an additional component selected from the group consisting of a vehicle, an additive, an excipient, a therapeutic compound, a pharmaceutical adjunct, a pharmaceutical agent useful in the treatment of the condition, a carrier and combinations thereof.
10. A method of treating a condition in a mammal, comprising:
 - administering a quantity of a non-steroidal anti-inflammatory drug (NSAID) to said mammal on a NSAID periodic basis; and
 - administering a quantity of a HER-kinase axis inhibitor to said mammal on a HER-kinase axis inhibitor periodic basis.
11. The method of claim 10, wherein the NSAID is selected from the group consisting of aspirin, diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sunlindac, tenoxicam, tiaprofenic acid, tolmetin, derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.
12. The method of claim 10, wherein the HER-kinase axis inhibitor is selected from the group consisting of recombinant humanized monoclonal antibody 2C4, ansamycins, gefitinib, erlotinib, monoclonal antibodies, rapamycin, src inhibitors, tyrosine kinase inhibitors, compound LY294002, imatinib mesylate, trastuzumab, compound CI1033, compound PKI166, compound GW2016, compound EKB569, compound IMC-C225, and derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.
13. The method of claim 10, wherein said NSAID is R-etodolac.
14. The method of claim 10, wherein said HER-kinase axis inhibitor is recombinant humanized monoclonal antibody 2C4.

15. The method of claim 10, wherein the quantity of said NSAID is from about 100 to about 500 mg/kg of said mammal.
16. The method of claim 10, wherein the quantity of said HER-kinase axis inhibitor is from about 5 to about 40 mg/kg of said mammal.
17. The method of claim 10, wherein the HER-kinase axis inhibitor periodic basis is twice weekly.
18. The method of claim 10, wherein the NSAID periodic basis is daily.
19. The method of claim 10, wherein administering said quantity of said NSAID and administering said quantity of said HER-kinase axis inhibitor further comprises using a delivery technique independently selected from the group consisting of intraperitoneal, oral gavage, intravenous, sublingual, topical, intramuscular, intra-arterial, intramedullar, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, parenteral, and rectal.
20. A kit for use in treating a condition in a mammal, comprising:
 - a quantity of a non-steroidal anti-inflammatory drug (NSAID);
 - a quantity of a HER-kinase axis inhibitor; and
 - instructions for use of said NSAID and said HER-kinase axis inhibitor in the treatment of said condition.
21. The kit of claim 20, wherein the NSAID is selected from the group consisting of aspirin, diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sunlindac, tenoxicam, tiaprofenic acid, tolmetin, derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.
22. The kit of claim 20, wherein the HER-kinase axis inhibitor is selected from the group consisting of recombinant humanized monoclonal antibody 2C4 (2C4),

ansamycins, gefitinib, erlotinib, monoclonal antibodies, rapamycin, src inhibitors, tyrosine kinase inhibitors, compound LY294002, imatinib mesylate, trastuzumab, compound CI1033, compound PKI166, compound GW2016, compound EKB569, compound IMC-C225, and derivatives thereof, analogs thereof, pharmaceutical equivalents thereof, and combinations thereof.

23. The kit of claim 20, wherein said NSAID is R-etodolac.
24. The kit of claim 20, wherein said HER-kinase axis inhibitor is recombinant humanized monoclonal antibody 2C4.
25. The kit of claim 20, wherein the instructions for use indicate that at least a portion of said quantity of said NSAID is to be administered to said mammal on an NSAID periodic basis, and that at least a portion of said quantity of said HER-kinase axis inhibitor is to be administered on a HER-kinase axis inhibitor periodic basis.
26. The kit of claim 25, wherein the HER-kinase axis inhibitor periodic basis is twice weekly.
27. The kit of claim 25, wherein the NSAID periodic basis is daily.
28. The kit of claim 20, wherein said NSAID and said HER-kinase axis inhibitor are each formulated for administration by a delivery technique independently selected from the group consisting of intraperitoneal, oral gavage, intravenous, sublingual, topical, intramuscular, intra-arterial, intramedullar, intrathecal, intraventricular, transdermal, subcutaneous, intranasal, parenteral, and rectal.